Published in Clinical Trials Week, May 11th, 2009
These presentations include data related to Durezol(TM) (difluprednate ophthalmic emulsion) 0.05%, fenretinide, and retinal research programs from the Sirion San Diego, CA based drug discovery laboratory.
Durezol (difluprednate ophthalmic emulsion) 0.05% was approved by the U.S. Food & Drug Administration (FDA) after an expedited review in June 2008 for the treatment of post-operative inflammation and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
Source: Clinical Trials Week (2009-05-11)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.